By Janet Fang
Posting in Design
The vaccine, known as Synflorix, is discounted 90%, making it the first time a vaccine is launched in rich and developing nations around the same time.
The pneumococcal bacterium (Streptococcus pneumoniae, pictured) causes diseases such as pneumonia, meningitis, and bacteremia (bacteria in blood), along with ear infections and bronchitis. Each year, these infections kill nearly one million children under 5. More than 70% are in developing countries.
Synflorix provides protection against 10 strains of S. pneumoniae. Nicaragua began vaccinating late last year. Guyana, Sierra Leone, and Yemen will as well. More than 40 developing countries will likely receive pneumococcal vaccines through AMC by 2015.
By guaranteeing the availability of initial purchase funds, AMC enables vaccine makers to invest in development and manufacturing [news release], and by contracting significant volumes over the long-term, manufacturers reduce the cost of their vaccines.
Synflorix received authorization from the European Commission in 2009. There’s usually a lag of nearly two decades before vaccines available to rich nations are made accessible to poor countries.
Across the developing world, this vaccine will have a ceiling price of $3.50 per dose, compared to the US price of close to $100. Nature reports:
Much of the small cost of the vaccine in developing countries will also be absorbed by the GAVI Alliance, explains Marina Krawczyk, who heads the AMC project for GAVI. "Right now most governments are paying around 15–30 cents per dose, but that will increase over time," she says.
At the end of the chain, the price for the end users is zero, says Shahnaaz Sharif, Kenya's director of public health and sanitation. "The Kenyan government is providing the vaccine free of charge at all public and private health facilities across the country."
Four companies have signed up with AMC so far. Last March, GlaxoSmithKline and Pfizer committed to 30 million doses each of their pneumococcal vaccines per year for the next 10 years. GSK has invested more than $400 million in a plant to manufacture Synflorix in Singapore to meet expected global demand. The Serum Institute and Panacea Biotec, both based in India, have also registered to provide the vaccine.
The AMC is backed by the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation, and 5 donor countries: UK, Canada, Russia, Norway, and Italy.
Image: CDC / Janice Carr via Wiki
Feb 15, 2011
What, and "evil" pharmaceutical company doing this? This can't be! @IMWeira, if AMC and others are financing the discount, then GSK doesn't have to charge US customers 190% since they are getting paid for the stuff. Not to mention that this disease in much less common in the US. AMC is financed by Bill Gates, among others.
When the government mandates a payback; the 90% cut back to African children means that the American market will pay 190% of the reasonable price of the drug. There is nothing free on earth. If one group gets something for "free" it means another group is paying for it. In this case, it is us. So if you want to thank someone, thank the American that will end up paying for it.
What about in the US? It seems like this vaccine would be beneficial to children everywhere. And what about use on adults? I don't want bronchitis, meningitis, pneumonia, or ear infections either...
This show the great work and commitment by AMC as for Glaxo Cline Smith they are in deep trouble due to pushing a danger diabetes drug. They have been ordered to payback 2.6 Billion to Diabetics http://www.clivir.com/lessons/show/2593.html This is a great story that possible shows the children will get a chance at a better life. (AMC) is doing a fantastic job to get the medication out at a 90% cut